• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Update: Annual Changes to the Nasdaq-100® Index

    12/12/23 6:00:00 PM ET
    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NDAQ alert in real time by email

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023.

    The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.

    Information

    For information about the company being added to the Nasdaq-100 Index® per this update, please visit the company website: Take-Two Interactive Software, Inc. – https://www.take2games.com/.

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Nasdaq Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -

    Media Relations ContactsInvestor Relations Contact  
    Name: Camille StaffordName: Index Client Services  
    Email: [email protected]

    Email  [email protected]  
      
    Name: Jennifer Lawson 
    Email: [email protected] 
      


    Primary Logo

    Get the next $NDAQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDAQ
    $PFE
    $SGEN
    $TTWO

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    11/20/2025$110.00Equal-Weight → Overweight
    Morgan Stanley
    Pfizer Inc.
    $PFE
    11/13/2025$30.00Sector Outperform
    Scotiabank
    Take-Two Interactive Software Inc.
    $TTWO
    10/23/2025$280.00Buy → Neutral
    Arete
    Take-Two Interactive Software Inc.
    $TTWO
    10/9/2025$270.00 → $300.00Buy
    DA Davidson
    Take-Two Interactive Software Inc.
    $TTWO
    7/28/2025$265.00Overweight
    Wells Fargo
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Srinivasan Laverne Evans sold $321,664 worth of shares (1,350 units at $238.27), decreasing direct ownership by 13% to 9,092 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    11/18/25 4:18:41 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    11/17/25 9:02:04 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sheresky Michael sold $42,790 worth of shares (182 units at $235.11), decreasing direct ownership by 0.28% to 65,781 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    11/17/25 5:01:01 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    SEC Filings

    View All

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NASDAQ upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded NASDAQ from Equal-Weight to Overweight and set a new price target of $110.00

    11/20/25 7:58:08 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Scotiabank initiated coverage on Pfizer with a new price target

    Scotiabank initiated coverage of Pfizer with a rating of Sector Outperform and set a new price target of $30.00

    11/13/25 9:16:05 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Take-Two downgraded by Arete with a new price target

    Arete downgraded Take-Two from Buy to Neutral and set a new price target of $280.00

    10/23/25 7:02:40 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 8-K filed by Pfizer Inc.

    8-K - PFIZER INC (0000078003) (Filer)

    11/21/25 4:16:49 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Pfizer Inc.

    424B5 - PFIZER INC (0000078003) (Filer)

    11/20/25 4:14:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Pfizer Inc.

    424B3 - PFIZER INC (0000078003) (Filer)

    11/18/25 8:15:34 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

    PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with muscle-invasive bladder cancer Approval is based on unprecedented data from the pivotal Phase 3 EV-303 trial showing a 60% reduction in the risk of disease recurrence, progression or death and a 50% reduction in the risk of death compared to surgery alone Represents the first and only ADC and PD-1 inhibitor regimen for this patient population and a potential new standard of care Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Aste

    11/21/25 1:24:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

    AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (JV) entity GMP Bio, driven by a new ind

    11/20/25 8:30:00 AM ET
    $BCAX
    $IOBT
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SGX Group to introduce Global Listing Board in Landmark Partnership with Nasdaq

    The two leading exchanges will create a new listing framework that bridges the U.S. and Singapore capital markets by enabling companies to raise capital, enhance visibility and access investors with ease SINGAPORE and NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- SGX Group (Singapore Exchange) and Nasdaq, Inc. (NASDAQ:NDAQ) today announced a partnership to simplify dual listings in the United States and Singapore, enabling companies with a market capitalisation of S$2 billion and above to access global capital, investors and liquidity through a harmonised cross-border listing framework that bridges the two markets. Scheduled to go live around mid-2026, this Global Listing Board deepens col

    11/19/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days

    11/12/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Take-Two Interactive Software, Inc. Reports Results for Fiscal Second Quarter 2026

    Company raises fiscal year 2026 outlook Fiscal second quarter Net Bookings were $1.96 billion, above Company's guidance range Net Bookings for fiscal year 2026 are now expected to range from $6.4 to $6.5 billion Grand Theft Auto VI now launching November 19, 2026 Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today reported results for the second quarter of its fiscal year 2026, ended September 30, 2025. For further information, please see the second quarter fiscal 2026 results slide deck posted to the Company's investor relations website at take2games.com/ir. CEO Comments Strauss Zelnick, Chairman and CEO of Take-Two Interactive, stated: "We achieved outstanding second quarter res

    11/6/25 4:05:00 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

    Focused Execution Delivers Strong EPS Performance Landmark Agreement Reached with U.S. Government Provides Longer-Term Business Clarity Secured Early FTC Clearance for Proposed Metsera Acquisition to Meaningfully Compete in Obesity Pfizer Inc. (NYSE:PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S. Government, which we believe provides greater clarity for our business. Additionally, our rec

    11/4/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Leadership Updates

    Live Leadership Updates

    View All

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puro.earth Secures €11 M Series B Financing Led by Nasdaq with Participation from Fortum Innovation & Venturing to strengthen its supplier infrastructure

    HELSINKI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Puro.earth, a leading carbon-crediting platform for engineered carbon dioxide removal (CDR), today announced it has raised €11 million in a Series B funding round led by Nasdaq with participation from Fortum Innovation & Venturing. Puro.earth will deploy this funding to strengthen the infrastructure that supports its best-in-class certification journey for suppliers. Key initiatives include enabling more frequent issuance of high-integrity carbon removal credits, facilitating offtake agreements, and advancing open integration of digital measurement, reporting, and verification (dMRV) tools. The new investment builds on a period of strong gr

    9/4/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Mafia: The Old Country Now Available Worldwide

    Dive into the roots of organized crime in 1900s Sicily with a compelling new cast of characters today Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment in the acclaimed Mafia franchise, is now available worldwide for PlayStation®5 (PS5®), Xbox Series X|S, and PC via Steam. The story will take players back in time to 1900s Sicily, which has been painstakingly created with the utmost authenticity and detail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808972468/en/Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment i

    8/8/25 10:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary